Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 10/20 | 0.63 |
| ▸ | KDM1B | Q8NB78 | 3/20 | 0.63 |
| ▸ | HTR2C | P28335 | 3/20 | 0.46 |
| ▸ | HTR2B | P41595 | 3/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.37 |
| ▸ | NOS2 | P35228 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 2/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL179047 | 0.84 | KDM1A (0.58) | KDM1AKDM1BHTR2CHTR2BHTR1A | |
| SCHEMBL13186510 | 0.79 | HTR2C (0.49) | KDM1AKDM1BHTR2CHTR2BCHRNB2 | |
| SCHEMBL179110 | 0.79 | KDM1A (0.66) | KDM1AKDM1BHTR2CHTR2BCHRNB2 | |
| SCHEMBL15541761 | 0.78 | KDM1A (1.00) | KDM1AKDM1BHTR2CHTR2BMAOA | |
| SCHEMBL28134528 | 0.78 | KDM1A (1.00) | KDM1AKDM1BHTR2CHTR2BMAOA | |
| SCHEMBL15541116 | 0.78 | KDM1A (1.00) | KDM1AKDM1BHTR2CHTR2BMAOA | |
| SCHEMBL12064742 | 0.77 | HTR2C (0.46) | KDM1AKDM1BHTR2CHTR2BCHRNB2 | |
| Hydrochloric Acid SCHEMBL16987728 | 0.76 | KDM1A (0.96) | KDM1AKDM1BHTR2CHTR2BMAOA | |
| SCHEMBL29941500 | 0.76 | CHRNB2 (0.47) | KDM1AKDM1BCHRNB2CHRNA4CHRNB4 | |
| SCHEMBL470620 | 0.76 | CHRNB2 (0.47) | KDM1AKDM1BCHRNB2CHRNA4CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120059014-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-03-08 | — | — | US | disclosed |
| WO-2010103334-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2010-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059014-A1 | Compounds for the Treatment of Metabolic Disorders | GPR119, FFAR2, GPBAR1 | KDM1A 4195/4885KDM1B 2993/4885HTR2C 1350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.